Press Releases

10 Oct 2017

EBE and EFPIA call on the EU Commission and Member States to improve transparency on Hospital Exemptions for Advanced Therapies

“Therapies for the future - Exploring solutions for innovative treatments in Europe” will take place at the European Parliament  on 11 October 2017. In advance of this significant discussion...

Read more
27 Sep 2017

ARM, EBE, EFPIA and EuropaBio jointly publish a series of proposals to streamline requirements and accelerate approvals of clinical trials with new therapies that consist of or contain Genetically Modified Organisms (GMOs) in Europe

The Alliance for Regenerative Medicine (ARM), the European Biopharmaceutical Enterprises (EBE), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and EuropaBio jointly publish a series of proposals to streamline requirements and accelerate approvals of clinical trials with new therapies that consist of or contain Genetically Modified Organisms (GMOs) in Europe....

Read more
29 Jun 2017

EFPIA, EBE and Vaccines Europe Back EU Leadership in Sustainable, Collaborative Fight Against AMR

The launch of the European Commission’s Action Plan on Antimicrobial Resistance (AMR) confirms the EU’s determination to take a leading role in combatting this phenomenon, by proposing concrete and innovative solutions to benefit patients worldwide....

Read more
26 Apr 2017

Intellectual Property: the key to innovation and survival for small and medium-sized biopharma companies

Today is World Intellectual Property day, an opportunity to reflect on the relevance of intellectual property rights to society where invention and innovation is valued for the greater benefit of all. ...

Read more
09 Mar 2017

EBE, EFPIA and IFPMA Have Today Launched a Position Paper Entitled “Considerations for Physicians on Switching Decisions Regarding Biosimilars”

Switching describes a physician's decision to exchange one product that a patient receives for another. With the introduction of biosimilars, physicians may be encouraged to switch patients from an original biologic (reference product) to any of its biosimilars (or vice versa) in order to reduce costs. ...

Read more
16 Feb 2017

EBE and EFPIA support ARM Initiative on Hospital Exemptions and Call for Increased Transparency on All Advanced Cell, Gene and Tissue Therapies

The European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) today express their support for key aspects of the “Positio...

Read more
19 Oct 2016

EFPIA and EBE Welcome NOR-SWITCH Results as a Valuable Step Forward

EFPIA and EBE welcome the results of the NOR-SWITCH study on biosimilar switching* and acknowledge its preliminary results as a step in the right direction of robust data generation that continues to enhance physician and patient confidence in using biosimilars. EFPIA and EBE also welcome the effort of the Norwegian authorities and investigators to initiate and carry out the NOR-SWITCH study....

Read more
19 Sep 2016

The European biotech ecosystem: EBE position paper recommends how to make funding go further

Brussels, 19 September 2016 The European Biopharmaceutical Enterprises (EBE) today published a White Paper that scrutinises funding available for innovative biopharmaceutical entrepreneurs in Europe and explores why fewer successful businesses are built in Europe – despite our exceptional science – than in other world regions....

Read more
17 Jun 2016

Compromise Agreement on IVDs is a Solid Step in the Right Direction to Enable Personalised Medicine

The European Biopharmaceutical Enterprises, EBE, and the European Federation of Pharmaceutical Industries and Associations, EFPIA, welcome the agreement reached between the Council of Ministers and the European Parliament Health Committee (ENVI) on the adoption of the Regulation on In-Vitro Diagnostic (IVD) Medical Devices. This Regulation, adopted alongside the Regulation on Medical Devices, will ensure the increased safety of IVD medical devices and will allow patients to benefit from innovative healthcare solutions in a timely manner....

Read more
16 Jun 2016

EBE, the European Biopharmaceutical Trade Association, Unveils Its Leadership 2016-2018

The European Biopharmaceutical Enterprises, EBE, is pleased to announce its Board of Directors for the term 2016-2018, following the decisions taken at the EBE and EFPIA (European Federation of Pharmaceutical Industries and Associations) Annual Meetings on 14 to 16 June 2016....

Read more
1 2 3